BioCentury | Nov 13, 2020
Product Development

A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

...of our clinical studies whether they be in heart failure, or diabetes, or asthma, or COPD.[00:18:46]...
BioCentury | Nov 11, 2020
Product Development

Medicare co-pays for COVID-19 mAbs scrapped, bamlanivimab distribution begins

...criteria for the EUA because they have cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD...
BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

...and IFNβ. Marsden said Synairgen’s data from COPD...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

...asthma. Regeneron also has the product in Phase II testing for chronic obstructive pulmonary disease (COPD...
BioCentury | Sep 11, 2020
Product Development

Sept. 10 Quick Takes: approvals for Zai, GSK and Phase III readouts for Satsuma, Amryt and Takeda; plus Houston Methodist, MassBio and JPM

...first LABA/LAMA/inhaled corticosteroid combination approved for the indication. Trelegy Ellipta was first approved to treat COPD...
BioCentury | May 1, 2020

CHMP backs new therapy for 1L AML, triple combos for asthma

...Ellipta umeclidinium bromide/fluticasone furoate/vilanterol from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) was approved in 2017 to treat COPD...
...LSE:AZN; NYSE:AZN) has its own triple combination, Breztri Aerosphere budesonide/glycopyrronium/formoterol fumarate (PT010), approved to treat COPD...
BioCentury | Mar 19, 2020
Product Development

Slotting anti-inflammatories into COVID-19 treatment

...benefit COVID-19 patients with ARDS. The company said that in a chronic obstructive pulmonary disease (COPD...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

...ongoing Phase II study of the inhaled formulation of IFNβ-1a in chronic obstructive pulmonary disease (COPD...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

...50%. The company said a post hoc analysis of a clinical chronic obstructive pulmonary disorder (COPD...
BioCentury | Mar 11, 2020
Politics, Policy & Law

FDA postpones meetings and inspections, grounds staff to combat COVID-19

...for Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol to reduce mortality in patients with chronic obstructive pulmonary disease (COPD...
Items per page:
1 - 10 of 1809